NSE - Delayed Quote INR

RPG Life Sciences Limited (RPGLIFE.NS)

1,541.95 +1.75 (+0.11%)
At close: April 24 at 3:29 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2023
3/31/2022
3/31/2021
Total Revenue
5,698,200.00
5,090,800.00
4,371,600.00
3,833,900.00
Cost of Revenue
1,899,400.00
1,782,300.00
1,502,100.00
1,376,400.00
Gross Profit
3,798,800.00
3,308,500.00
2,869,500.00
2,457,500.00
Operating Expense
2,713,200.00
2,419,700.00
2,152,300.00
1,910,300.00
Operating Income
1,085,600.00
888,800.00
717,200.00
547,200.00
Net Non Operating Interest Income Expense
15,300.00
15,800.00
-800.00
-14,700.00
Pretax Income
1,139,100.00
916,800.00
731,700.00
535,800.00
Tax Provision
291,400.00
240,400.00
216,900.00
135,800.00
Net Income Common Stockholders
847,700.00
676,400.00
514,800.00
400,000.00
Diluted NI Available to Com Stockholders
847,700.00
676,400.00
514,800.00
400,000.00
Basic EPS
51.26
40.90
31.13
24.19
Diluted EPS
51.26
40.90
31.13
24.19
Basic Average Shares
16,538.34
16,539.02
16,539.02
16,539.02
Diluted Average Shares
16,538.34
16,539.02
16,539.02
16,539.02
Rent Expense Supplemental
8,200.00
6,900.00
6,600.00
7,000.00
Total Expenses
4,612,600.00
4,202,000.00
3,654,400.00
3,286,700.00
Net Income from Continuing & Discontinued Operation
847,700.00
676,400.00
514,800.00
400,000.00
Normalized Income
842,788.39
671,531.18
509,171.20
401,269.05
Interest Income
1,700.00
27,300.00
13,300.00
3,200.00
Interest Expense
3,600.00
3,100.00
5,200.00
7,900.00
Net Interest Income
15,300.00
15,800.00
-800.00
-14,700.00
EBIT
1,142,700.00
919,900.00
736,900.00
543,700.00
EBITDA
1,307,400.00
1,074,900.00
893,500.00
708,400.00
Reconciled Cost of Revenue
1,899,400.00
1,782,300.00
1,502,100.00
1,376,400.00
Reconciled Depreciation
164,700.00
155,000.00
156,600.00
164,700.00
Net Income from Continuing Operation Net Minority Interest
847,700.00
676,400.00
514,800.00
400,000.00
Total Unusual Items Excluding Goodwill
6,600.00
6,600.00
8,000.00
-1,700.00
Total Unusual Items
6,600.00
6,600.00
8,000.00
-1,700.00
Normalized EBITDA
1,300,800.00
1,068,300.00
885,500.00
710,100.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
1,688.39
1,731.18
2,371.20
-430.95
3/31/2021 - 8/12/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KILITCH.NS Kilitch Drugs (India) Limited
346.30
-1.45%
 
KILITCH.BO Kilitch Drugs (India) Limited
349.60
+0.16%
 
ALBERTDAVD.NS Albert David Limited
1,193.80
-0.36%
 
JAGSNPHARM.BO Jagsonpal Pharmaceuticals Limited
321.00
-1.59%
 
JAGSNPHARM.NS Jagsonpal Pharmaceuticals Limited
320.65
-1.52%
 
LINCOLN.NS Lincoln Pharmaceuticals Limited
593.30
-1.08%
 
INDOCO.NS Indoco Remedies Limited
329.00
-0.14%
 
MANGALAM.NS Mangalam Drugs & Organics Limited
101.75
+0.10%
 
WINDLAS.BO Windlas Biotech Limited
559.60
+1.35%
 
ERIS.NS Eris Lifesciences Limited
870.10
-1.46%